Once weekly semaglutide/placebo subcuteneous injection, dose 2.4 mg.

2 trials

Sponsors

Novo Nordisk

Conditions

obesitas hartfailure obesityobesitas heartfailure obesity

Phase 3

Effect of semaglutide 2.4 mg once weekly on function and symptoms in subjects with obesity-related heart failure with preserved ejection fraction.

Active, not recruitingNL-OMON51952

Novo Nordiskobesitas heartfailure obesity

Start: 2021-04-20Target: 25Updated: 2024-04-09

Effect of Semaglutide 2.4 mg once-weekly on function and symptoms in subjects with obesity-related heart failure with preserved ejection fraction, and type 2 diabetes

Active, not recruitingNL-OMON51963

Novo Nordiskobesitas hartfailure obesity

Start: 2021-08-24Target: 25Updated: 2024-04-09